KEMOPLAT (Cisplatin Injection) is indicated as therapy to be employed as follows:
Metastatic Testicular Tumors :
In established combination therapy with other approved chemotherapeutic agents in patients with metastatic testicular tumors who have already received appropriate surgical and/or radio therapeutic procedures
Metastatic Ovarian Tumors :
In established combination therapy with other approved chemotherapeutics agents in patients with metastatic ovarian tumors who have already received appropriate surgical and/or radio therapeutic procedures. An established combination consists of cisplatin and cyclophosphamide. Cisplatin, as a single agent, is indicated as secondary therapy in patients with metastatic ovarian tumors refractory to standard chemotherapy who have not previously received cisplatin therapy
Advanced Bladder Cancer :
Cisplatin is indicated as a single agent for patients with transitional cell bladder cancer, which is no longer amenable to local treatments such as surgery and / or radiotherapy.
KEMOPLAT (Cisplatin Injection 1.0mg/ml) is available as 10ml and 50ml single dose vial containing 10 mg & 50 mg of cisplatin, respectively.